Krystal Biotech Inc (KRYS)
Solvency ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.12 | 1.05 | 1.07 | 1.06 | 1.06 |
Krystal Biotech Inc has consistently maintained a strong solvency position over the years, as evident from its solvency ratios. The debt-to-assets, debt-to-capital, and debt-to-equity ratios have all been at 0.00 for each year from 2020 to 2024. This indicates that the company has had no debt relative to its assets, capital, or equity during this period.
Additionally, the financial leverage ratio has shown some fluctuations, ranging from 1.05 to 1.12 between 2020 and 2024. While these fluctuations are relatively minor, they still indicate a slight increase in financial leverage over the years, potentially signaling a shift towards utilizing more debt financing compared to equity.
Overall, the consistently low debt ratios and relatively stable financial leverage ratio suggest that Krystal Biotech Inc has a low level of financial risk and a solid solvency position throughout the analyzed period.
Coverage ratios
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | |
|---|---|---|---|---|---|
| Interest coverage | — | — | — | -45.63 | — |
The interest coverage ratio is a measure of a company's ability to meet its interest obligations on outstanding debt. In the case of Krystal Biotech Inc, the interest coverage for December 31, 2020, is not available as indicated by "\u2014". For December 31, 2021, the interest coverage ratio is calculated at -45.63. This negative value suggests that the company's earnings before interest and taxes (EBIT) are insufficient to cover its interest expenses during that period. The negative ratio indicates potential financial risk, as the company's income may not be adequate to cover its interest payments.
As for the years 2022, 2023, and 2024, the interest coverage ratios are not available and denoted as "\u2014". The absence of data for these years makes it difficult to evaluate the trend in the company's ability to cover interest expenses over time. In summary, based on the available information, Krystal Biotech Inc faced challenges in covering its interest obligations in 2021, highlighting a potential strain on its financial position and the need for further analysis to understand the factors contributing to the negative interest coverage ratio.